Pre-Clinical Development of a Novel Therapeutic Vaccine for Chronic Hepatitis B

在欧洲，估计有1400万公民患有慢性肝炎B病毒（HBV）感染，其中近四分之一将死于肝衰竭或肝癌，这是病毒感染的直接结果，每年有> 36，000人死亡。因此，HBV通过治疗的直接成本以及与生产力损失和过早死亡相关的间接成本，对整个欧洲的医疗保健系统构成重大负担。免疫靶向系统（ITS）正在开发一种新型的氟肽疫苗免疫疗法（Hepsyn-B），基于其专有的Depovaccine和Densigen技术，以诱导对疾病的免疫控制，增加清除受感染肝细胞的可能性，并减少对长期昂贵药物治疗的需求。该项目为加快Hepsyn-B的临床前开发提供了机会，并证明了疫苗的安全性，有效性和可制造性，为人类临床试验做准备。

In Europe there are an estimated 14 million citizens living with chronic hepatitis B virus (HBV) infection, nearly a quarter of those will die of liver failure or liver cancer as a direct result of the viral infection, accounting for >36,000 deaths per annum. As a consequence HBV is a significant burden to healthcare systems across Europe through the direct costs of treatment, as well as indirect costs linked to lost productivity and premature death. Immune Targeting Systems (ITS) is developing a novel fluoropeptide vaccine immunotherapy (Hepsyn-B), based on its proprietary Depovaccine and Densigen technologies, to induce immune control over the disease, increase likelihood of the clearance of infected liver cells and reducing the need for prolonged costly drug therapy. This project provides the opportunity to expedite the pre-clinical development of Hepsyn-B and demonstrate vaccine safety, efficacy and manufacturability in preparation for human clinical trials.